Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)
暂无分享,去创建一个
F. Cardoso | E. Starosławska | E. Petru | R. Bartsch | M. Cazzaniga | G. Freyer | J. Haba | G. Villanova | L. Costa | C. Almeida